Oral emixustat hydrochloride reduced central subfield retinal thickness more than placebo in patients with proliferative diabetic retinopathy, with and without macular edema, Acucela announced in a press release.
The randomized, placebo-controlled, phase 2 trial enrolled 24 subjects to receive placebo or the study drug, titrated up to 40 mg per day. Patients in the study group experienced a mean reduction in central subfield thickness of 48.1 µm (P = .0764), as well as a mean reduction in total macular volume (P = .0263), compared with placebo.
“We are thrilled to (Read more...)
Uncategorized